Alkem Laboratories Limited (NSE: ALKEM) becomes the first in India to launch semaglutide in single-shot pre-filled syringes starting at INR 350.
Alkem Laboratories Limited (ALKEM) reports record high EBITDA and strong revenue growth for Q4 & FY26, with notable performance in domestic and international.
